A股異動 | 會稽山連續第二日跌停 控股股東破產重整投資人並非傳言的華潤、復星
格隆匯5月18日丨因控股股東重整的傳聞,黃酒上市公司會稽山在過去一個月內股價翻倍,獲得多個漲停板。然而,在公佈意向投資人消息後,會稽山卻連續第二日跌停,現報16.36元,總市值81億元。4月中旬以來,由於控股股東精功集團破產重整的相關傳聞,會稽山股價異動。進入5月後,會稽山曾創下10天獲得6個漲停板,過去一個月內5次登上龍虎榜,股價實現翻倍。5月16日晚間,會稽山發佈公吿稱,控股股東破產重整投資人終於現身。不過,此前外界傳言的華潤、復星等巨頭並未出現在意向投資人名單中,根據會稽山公吿,繳納盡調保證金並正式報名成功的意向投資人共1名,為中建信控股集團有限公司。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.